ATE205081T1 - Dreiphasen-pharmazeutische form mit konstanter und gesteuerter freisetzung eines amorphen wirkstoffs zur einmaligen täglichen anwendung - Google Patents

Dreiphasen-pharmazeutische form mit konstanter und gesteuerter freisetzung eines amorphen wirkstoffs zur einmaligen täglichen anwendung

Info

Publication number: ATE205081T1
Authority: AT; Austria
Prior art keywords: active ingredient; phase; amorphous; pharmaceutical form; pct
Prior art date: 1995-05-19

Application number

AT96915292T

Other languages

English (en)

Inventor

Janez Kerc

Ljubomira Barbara Rebic

Bojan Kofler

Original Assignee

Lek Tovarna Farmacevtskih

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-19

Filing date

1996-05-17

Publication date

2001-09-15

1996-05-17 Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih

2001-09-15 Application granted granted Critical

2001-09-15 Publication of ATE205081T1 publication Critical patent/ATE205081T1/de

Links

239000004480 active ingredient Substances 0.000 title abstract 11
238000013270 controlled release Methods 0.000 title abstract 3
229920003086 cellulose ether Polymers 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
238000002360 preparation method Methods 0.000 abstract 2
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 abstract 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 abstract 1
LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 abstract 1
238000010521 absorption reaction Methods 0.000 abstract 1
JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000011248 coating agent Substances 0.000 abstract 1
238000000576 coating method Methods 0.000 abstract 1
239000013078 crystal Substances 0.000 abstract 1
238000002425 crystallisation Methods 0.000 abstract 1
230000008025 crystallization Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
239000007888 film coating Substances 0.000 abstract 1
238000009501 film coating Methods 0.000 abstract 1
210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000002245 particle Substances 0.000 abstract 1
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1
229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1
238000013268 sustained release Methods 0.000 abstract 1
239000012730 sustained-release form Substances 0.000 abstract 1
150000003626 triacylglycerols Chemical class 0.000 abstract 1
229920003169 water-soluble polymer Polymers 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT96915292T 1995-05-19 1996-05-17 Dreiphasen-pharmazeutische form mit konstanter und gesteuerter freisetzung eines amorphen wirkstoffs zur einmaligen täglichen anwendung ATE205081T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SI9500173A SI9500173B (sl)	1995-05-19	1995-05-19	Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
PCT/SI1996/000012 WO1996036318A2 (en)	1995-05-19	1996-05-17	Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application

Publications (1)

Publication Number	Publication Date
ATE205081T1 true ATE205081T1 (de)	2001-09-15

Family

ID=20431627

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96915292T ATE205081T1 (de)	1995-05-19	1996-05-17	Dreiphasen-pharmazeutische form mit konstanter und gesteuerter freisetzung eines amorphen wirkstoffs zur einmaligen täglichen anwendung

Country Status (15)

Country	Link
US (1)	US6042847A (de)
EP (1)	EP0827397B1 (de)
JP (1)	JPH11505542A (de)
AT (1)	ATE205081T1 (de)
AU (1)	AU698360B2 (de)
CZ (1)	CZ288598B6 (de)
DE (1)	DE69615017D1 (de)
HU (1)	HUP9901457A3 (de)
PL (1)	PL184183B1 (de)
RO (1)	RO117148B1 (de)
RU (1)	RU2161956C2 (de)
SI (1)	SI9500173B (de)
SK (1)	SK282000B6 (de)
UA (1)	UA42062C2 (de)
WO (1)	WO1996036318A2 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5696135A (en)	1995-06-07	1997-12-09	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
IT1284604B1 (it) *	1996-09-27	1998-05-21	Roberto Valducci	Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
FR2758459B1 (fr) *	1997-01-17	1999-05-07	Pharma Pass	Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2783421B1 (fr) *	1998-09-17	2000-11-24	Cll Pharma	Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
IL143197A0 (en) *	1998-11-20	2002-04-21	Rtp Pharma Inc	Dispersible phospholipid stabilized microparticles
US6814977B1 (en)	1998-12-18	2004-11-09	Abbott Laboratories	Formulations comprising lipid-regulating agents
US6838091B2 (en)	1998-12-18	2005-01-04	Abbott Laboratories	Formulations comprising lipid-regulating agents
US7014864B1 (en)	1998-12-18	2006-03-21	Abbott Laboratories	Formulations comprising lipid-regulating agents
US6706283B1 (en)	1999-02-10	2004-03-16	Pfizer Inc	Controlled release by extrusion of solid amorphous dispersions of drugs
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6719999B2 (en)	1999-03-31	2004-04-13	Abbott Laboratories	Formulations comprising lipid-regulating agents
US6465011B2 (en) *	1999-05-29	2002-10-15	Abbott Laboratories	Formulations comprising lipid-regulating agents
CA2377301C (en)	1999-06-14	2009-05-12	Cosmo S.P.A.	Controlled release and taste masking oral pharmaceutical compositions
US8895064B2 (en)	1999-06-14	2014-11-25	Cosmo Technologies Limited	Controlled release and taste masking oral pharmaceutical composition
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6982281B1 (en)	2000-11-17	2006-01-03	Lipocine Inc	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9920558D0 (en) *	1999-08-31	1999-11-03	Bradford Particle Design Ltd	Methods for particle formation and their products
HK1049834A1 (zh)	1999-10-11	2003-05-30	辉瑞大药厂	用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
EP1175205B1 (de) *	1999-11-12	2006-06-14	Abbott Laboratories	Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
RU2169557C1 (ru) *	1999-12-22	2001-06-27	Александр Афанасьевич Яремчук	Сироп амброксола для лечения бронхопульмональных заболеваний
DE10026698A1 (de) *	2000-05-30	2001-12-06	Basf Ag	Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8586094B2 (en) *	2000-09-20	2013-11-19	Jagotec Ag	Coated tablets
EP1320362B1 (de) *	2000-09-20	2011-08-31	Jagotec AG	Stabilisierte fibrat-mikropartikel
FR2819720B1 (fr) *	2001-01-22	2004-03-12	Fournier Lab Sa	Nouveaux comprimes de fenofibrate
US20080058424A1 (en) *	2002-05-23	2008-03-06	Cephalon, Inc.	Novel pharmaceutical formulations of modafinil
EP1269994A3 (de) *	2001-06-22	2003-02-12	Pfizer Products Inc.	Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
PE20030324A1 (es) *	2001-07-31	2003-04-03	Warner Lambert Co	Composiciones farmaceuticas de amlodipina y atorvastatina
CN1625397A (zh)	2002-02-01	2005-06-08	辉瑞产品公司	胆固醇酯转移蛋白抑制剂的控制释放药物剂型
US7229644B2 (en) *	2002-05-23	2007-06-12	Cephalon, Inc.	Pharmaceutical formulations of modafinil
US7445796B2 (en) *	2002-08-19	2008-11-04	L. Perrigo Company	Pharmaceutically active particles of a monomodal particle size distribution and method
US20040116532A1 (en)	2002-09-13	2004-06-17	Craig Heacock	Pharmaceutical formulations of modafinil
EP1400835B1 (de) *	2002-09-17	2011-11-16	Nippon Telegraph And Telephone Corporation	Optischer Halbleitermodulator und Laser mit einem solchen Modulator
CN101480384A (zh) *	2002-12-17	2009-07-15	阿伯特有限及两合公司	包含非诺贝酸、其生理可接受的盐或衍生物的制剂
US20080051411A1 (en) *	2002-12-17	2008-02-28	Cink Russell D	Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US8377952B2 (en) *	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
US20060003002A1 (en) *	2003-11-03	2006-01-05	Lipocine, Inc.	Pharmaceutical compositions with synchronized solubilizer release
KR100598326B1 (ko)	2004-04-10	2006-07-10	한미약품 주식회사	ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
CN101810882B (zh) *	2004-09-24	2013-07-24	Hi-Lex株式会社	机体硬组织或软组织诱导性支架材料
WO2006066932A1 (en) *	2004-12-24	2006-06-29	Lek Pharmaceuticals D.D.	Stable pharmaceutical composition comprising an active substance in the form of solid solution
EP1785133A1 (de) *	2005-11-10	2007-05-16	Laboratoires Fournier S.A.	Verwendung von Fenofibrate oder dessen Derivaten zur Prävention von diabetischer retinopathie
CN101410094B (zh) *	2006-01-27	2013-04-17	阿普塔利斯制药股份有限公司	包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
EP1837020A1 (de) *	2006-03-24	2007-09-26	Bioalliance Pharma	Bioadhäsive Schleimhautträger zur langsamen Verabreichung von aktiven Substanzen
US9254266B2 (en) *	2007-03-21	2016-02-09	Wisconsin Alumni Research Foundation	Inhibiting surface enhanced crystallization of amorphous pharmaceuticals with ultrathin coatings
DE102007048705A1 (de) *	2007-10-11	2009-04-16	Bayer Healthcare Ag	Amorphe Formulierung
WO2009085766A2 (en) *	2007-12-19	2009-07-09	Mutual Pharmaceutical Company, Inc.	Fenofibric acid amorphous dispersion; method of making; and method of use thereof
US20090187040A1 (en) *	2008-01-18	2009-07-23	Tong Sun	Fenofibric acid polymorphs; methods of making; and methods of use thereof
CA2718416C (en) *	2008-03-13	2018-01-02	Mallinckrodt Inc.	Multi-function, foot-activated controller for imaging system
US20100160363A1 (en) *	2008-12-19	2010-06-24	Aaipharma Services Corp.	Extended-release pharmaceutical formulations
US20100159001A1 (en) *	2008-12-19	2010-06-24	Cardinal John R	Extended-Release Pharmaceutical Formulations
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US8937150B2 (en)	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
EA020031B1 (ru) *	2009-06-11	2014-08-29	Эббви Бахамаз Лтд.	Противовирусные соединения
SMT202000093T1 (it)	2009-06-16	2020-03-13	Pfizer	Forme di dosaggio di apixaban
NZ605440A (en)	2010-06-10	2014-05-30	Abbvie Bahamas Ltd	Solid compositions comprising an hcv inhibitor
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US10154964B2 (en)	2011-09-07	2018-12-18	Cosmo Technologies Limited	Controlled release and taste masking oral pharmaceutical composition
US9034832B2 (en)	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
US20160213575A1 (en) *	2013-09-11	2016-07-28	3M Innovative Properties Company	Coating compositions, dental structures thereof and methods for generating contrast
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
WO2016033549A2 (en)	2014-08-28	2016-03-03	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
TWI525103B (zh)	2014-12-29	2016-03-11	財團法人工業技術研究院	改質纖維素與及應用其之複合材料
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
WO2020018974A1 (en)	2018-07-20	2020-01-23	Lipocine Inc.	Liver disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1579818A (en) *	1977-06-07	1980-11-26	Yamanouchi Pharma Co Ltd	Nifedipine-containing solid preparation composition
US4259314A (en) *	1979-12-10	1981-03-31	Hans Lowey	Method and composition for the preparation of controlled long-acting pharmaceuticals
US5264446A (en) *	1980-09-09	1993-11-23	Bayer Aktiengesellschaft	Solid medicament formulations containing nifedipine, and processes for their preparation
US4327725A (en) *	1980-11-25	1982-05-04	Alza Corporation	Osmotic device with hydrogel driving member
US4389393A (en) *	1982-03-26	1983-06-21	Forest Laboratories, Inc.	Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) *	1983-05-11	1986-09-16	Alza Corporation	Osmotic device with dual thermodynamic activity
US4783337A (en) *	1983-05-11	1988-11-08	Alza Corporation	Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) *	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
EP0227814A1 (de) *	1985-07-02	1987-07-08	The Upjohn Company	Therapeutische zusammensetzungen mit bimodalabgabe-charakteristiken
US5015479A (en) *	1987-02-02	1991-05-14	Seamus Mulligan	Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4786503A (en) *	1987-04-06	1988-11-22	Alza Corporation	Dosage form comprising parallel lamine
DE3720757A1 (de) *	1987-06-24	1989-01-05	Bayer Ag	Dhp-manteltablette
US4792452A (en) *	1987-07-28	1988-12-20	E. R. Squibb & Sons, Inc.	Controlled release formulation
US5009895A (en) *	1990-02-02	1991-04-23	Merck & Co., Inc.	Sustained release with high and low viscosity HPMC
BE1004243A3 (fr) *	1990-05-17	1992-10-20	Europharmaceuticals Sa	Compositions pharmaceutiques du type a liberation prolongee destinees a l'administration par voie orale et leur procede de preparation.
DE4226753A1 (de) *	1992-08-13	1994-02-17	Basf Ag	Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
IT1264517B1 (it) *	1993-05-31	1996-09-24	Ekita Investments Nv	Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
HU213407B (en) *	1993-12-09	1997-06-30	Egyt Gyogyszervegyeszeti Gyar	Process for producing tablet with diffusive-osmotic release

1995
- 1995-05-19 SI SI9500173A patent/SI9500173B/sl not_active IP Right Cessation
1996
- 1996-05-17 PL PL96323487A patent/PL184183B1/pl unknown
- 1996-05-17 US US08/945,984 patent/US6042847A/en not_active Expired - Fee Related
- 1996-05-17 CZ CZ19973655A patent/CZ288598B6/cs not_active IP Right Cessation
- 1996-05-17 EP EP96915292A patent/EP0827397B1/de not_active Expired - Lifetime
- 1996-05-17 SK SK1534-97A patent/SK282000B6/sk unknown
- 1996-05-17 RU RU97120754/14A patent/RU2161956C2/ru not_active IP Right Cessation
- 1996-05-17 AU AU57103/96A patent/AU698360B2/en not_active Ceased
- 1996-05-17 WO PCT/SI1996/000012 patent/WO1996036318A2/en not_active Ceased
- 1996-05-17 JP JP8534769A patent/JPH11505542A/ja active Pending
- 1996-05-17 UA UA97115512A patent/UA42062C2/uk unknown
- 1996-05-17 DE DE69615017T patent/DE69615017D1/de not_active Expired - Lifetime
- 1996-05-17 RO RO97-02138A patent/RO117148B1/ro unknown
- 1996-05-17 HU HU9901457A patent/HUP9901457A3/hu unknown
- 1996-05-17 AT AT96915292T patent/ATE205081T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU5710396A (en)	1996-11-29
AU698360B2 (en)	1998-10-29
CZ365597A3 (cs)	1998-04-15
RU2161956C2 (ru)	2001-01-20
UA42062C2 (uk)	2001-10-15
SK282000B6 (sk)	2001-10-08
PL184183B1 (pl)	2002-09-30
CZ288598B6 (cs)	2001-07-11
WO1996036318A3 (en)	1997-01-16
SK153497A3 (en)	1998-04-08
HUP9901457A2 (hu)	1999-08-30
EP0827397A2 (de)	1998-03-11
WO1996036318A2 (en)	1996-11-21
HUP9901457A3 (en)	2000-06-28
SI9500173B (sl)	2002-02-28
RO117148B1 (ro)	2001-11-30
SI9500173A (en)	1996-12-31
EP0827397B1 (de)	2001-09-05
JPH11505542A (ja)	1999-05-21
DE69615017D1 (de)	2001-10-11
US6042847A (en)	2000-03-28
PL323487A1 (en)	1998-03-30

Legal Events

Date	Code	Title	Description
2002-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE205081T1 (de)	2001-09-15	Dreiphasen-pharmazeutische form mit konstanter und gesteuerter freisetzung eines amorphen wirkstoffs zur einmaligen täglichen anwendung
EP0381219B1 (de)	1993-05-05	Mittel auf Gemfibrozilbasis mit modifizierter Freigabe
AU3928501A (en)	2001-09-24	Multilayer pharmaceutical product for release in the colon
ATE222505T1 (de)	2002-09-15	Flüssige polymerzusammensetzung und verfahren zu ihrer verwendung
BR9407749A (pt)	1997-02-12	Derivados de ácido processo para a preparaçao dos mesmos e composiçoes farmacêuticas
DE59008238D1 (de)	1995-02-23	4-Hydroxytetrahydropyran-2-one sowie die entsprechenden Dihydroxycarbonsäurederivate, Salze und Ester, Verfahren zu ihrer Herstellung, pharmazeutische Präparate sowie Vorprodukte.
CN101437500B (zh)	2011-10-26	用于透皮吸收的组合物和包含由其形成的聚合基质的制剂
JPH02202813A (ja)	1990-08-10	経皮吸収製剤
JPH0827003A (ja)	1996-01-30	経皮吸収製剤
AU4339797A (en)	1998-04-14	Viral inhibition by long-chain alcohols, alkanes, fatty acids and amides
AU623731B2 (en)	1992-05-21	Water dispersible gemfibrozil compositions
MXPA04006256A (es)	2005-03-31	Formulaciones transdermicas adhesivas de diclofenac sodico.
JPH0892080A (ja)	1996-04-09	経皮吸収用製剤
JP2516524B2 (ja)	1996-07-24	持続性製剤
JPH11199521A (ja)	1999-07-27	皮膚外用剤
RU2001122815A (ru)	2004-02-20	Фармацевтическая смесь, содержащая сочетание профена и других активных соединений
JP3427445B2 (ja)	2003-07-14	クリーム剤
GR1004058B (el)	2002-11-15	Φωτοπολυμερικα υλικα με βιοσυμβατες λιθογραφικες απαιτησεις καταλληλα για σχηματοποιηση επιστρωσεων πολλαπλων βioμοριων
CA2414753C (en)	2009-09-01	Dermal therapeutic system containing 2-(3-benzophenyl)-propionic acid or [0-(2,6-dichloranilino)-phenyl]-ethanoic acid
JPS62240613A (ja)	1987-10-21	貼付剤
JPH0753670B2 (ja)	1995-06-07	経皮・経粘膜製剤
JP2002212064A (ja)	2002-07-31	化粧品、医薬品貼付剤用基材
ES2172172T3 (es)	2002-09-16	Composiciones farmaceuticas solidas para la administracion por via oral que permiten la liberacion modulada de nicorandil y su procedimiento de preparacion.
JPH09169636A (ja)	1997-06-30	貼付剤
JP2006257188A (ja)	2006-09-28	水性ポリマー組成物分散物